The interim data demonstrate the positive effects of CVac treatment on the immune system.

The Company has completed intracellular cytokine staining ("ICS") analysis of seven patients from the CAN-003 trial -- five patients from the CVac group and two patients from the control group, who did not receive any cancer treatment during the study.

As compared to the control group, the CVac patients demonstrated much higher T cell activity throughout the testing period. ICS testing also indicates that the T cell response is specific to mucin 1, the antigen marker present on most ovarian cancer cells.

Prof. Ian Frazer, the chairman of Prima's scientific advisory board commented: "There is clear evidence of a cellular response to mucin 1 induced by CVac treatment. We look forward to further analysis of all patients on the CAN-003 study to see if these early trends are confirmed."

Matthew Lehman, Prima's CEO, stated: "We are encouraged by the interim trends we have seen in the CAN-003 data released to date. CVac has a very favourable side effect profile, the clinical data in terms of progression free survival are trending in the right direction, and the early ICS data support our hypothesis of how the product should work in a patient's body."

ICS is a laboratory technique used to evaluate if CVac has induced a desired mucin 1 specific T cell response in patients treated with CVac. The ICS results help confirm the biological activity of CVac.

Prima will make a presentation of the CAN-003 interim data via a conference call and webcast on Thursday November 15th at 9:00am (Sydney local time).

Before launching the webcast, it is recommended to click on the link and then on "Test your systems configuration." A replay of the teleconference and webcast will be available through Prima's website following the live event.

About Prima BioMedPrima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.

About CAN-003CAN-003 is an open label, randomized, multinational, controlled phase 2 study. Sixty-three ovarian cancer patients in first or second remission have been enrolled. The first seven patients were not randomized and all received CVac. Subsequently, 29 patients were randomized to the CVac group compared to 27 patients in the observation standard of care group.